

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of May 30 – June 3, 2011

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Mark your calendars for resident graduation on Friday, June 17, 2011. Details to follow.

Meetings

Monday	05/30/11		Holiday – Memorial Day
Thursday	06/02/11	8:00 a.m.	Call Center Meeting
			<u>Resident Lectures:</u>
		8:00 a.m.	PGY-1 – “Introduction to Psychopharmacology” Dr. Carlos Santana
			PGY-2 – “Geriatric Psychiatry – Bipolar in the Elderly” Dr. Elizabeth Vidal
			PGY-3 – “Interpersonal Psychotherapy” Dr. Robert Fernandez
			CHILD – Language “NL Language Development” Dr. Brenda Curtwright
		9:00 a.m.	PGY-1 – “Clinical Neurosciences – Neuroimaging” Dr. Sara Reading
			PGY-2 – “Geriatric Psychiatry – Anxiety Disorders in the Elderly” Dr. Jean Fils
			PGY-3 – “Clinical Case Conference” Beth Reese, LCSW
			PGY-4 – “Neurology Review” Dr. Gabriel de Erausquin
			CHILD – “Language” Dr. Brenda Curtwright
		10:00 a.m.	PGY-2 – “Introduction to Child and Adolescent – Pervasive Developmental Disorders I” Dr. Sandra Stock
			PGY-3 – “Advanced Psychopharmacology” Thea Moore, Pharm D
			PGY-4 – “Neurology Review” Dr. Gabriel de Erausquin
			CHILD – “Language” Dr. Brenda Curtwright

11:00 a.m. Residents Meeting

12:00 noon NO GRAND ROUNDS

1:00 p.m. GERI – “Involuntary Weight Loss” Dr. Jonathan Stewart

Friday 06/03/11

No Medical Student Lectures

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Abilify IM Depot Study

ENROLLMENT ENDING SOON

Participants in this study can now continue to receive open-label Aripiprazole IM Depot until it is FDA approved up to a maximum of 8 years. Our site can enroll up to 6 additional subjects in this study through January, 2011. Participants are started on oral Abilify – once tolerability is determined, the participant is switched to Aripiprazole IM Depot. Aripiprazole IM Depot is administered monthly. All study related medications, labs, ECGs and study visits are at no charge to participants throughout the duration of the extension study (remember up to 8 years or until drug is FDA approved). Principal Investigator – Carlos Santana, M.D.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

NEW AUTISM STUDY

We are happy to announce USF Psychiatry’s participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases – a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator – Mike Bengtson, MD.

Schizophrenia PRIDE Study – Jail Recidivism

A 15- month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator – Jean Fils, M.D.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>